We’re supporting clients through every stage of their brand and product lifecycle.
Our centers of expertise span therapeutic areas, markets and geographies, and are underpinned by these four core research principles:
Successful MedTech research with rare-disease patients hinges on empathy, flexibility, and creativity in recruitment, moderation, and analysis.
The new pulmonary arterial hypertension (PAH) study is launching in the US market, with new markets being added in early 2024. .
Did you know that the number of rare disease patients in China is estimated to be more than 20 million, with more than 200,000 new cases registered?
How we explored the opportunity for an existing auto-immune product to be used in the treatment of another more low-prevalence orphan disease.
How we generated insights with an extremely small and difficult to reach audience across multiple markets to support a new product development.
Advances in understanding and treatment are reforming pharma's approach to the management of this rare disease. What does the landscape look like now?
Market opportunity as well as our experience and expertise in the growing area of rare diseases and orphan drugs.
The key challenges of conducting rare disease market research and how do we overcome them using a range of small sample analytical techniques.
Manufacturers of orphan drugs are being awarded longer market exclusivity, reduced regulatory fees and tax incentives.
Rapport is our monthly newsletter where we share our latest expertise and experience.
